Literature DB >> 20155993

Atorvastatin-induced prolonged cholestasis with bile duct damage.

Manuela Merli1, Maria Consiglia Bragazzi, Federica Giubilo, Francesco Callea, Adolfo F Attili, Domenico Alvaro.   

Abstract

We report a case of acute-onset, long-lasting cholestasis induced by atorvastatin. This antihyperlipidaemic drug was taken for 40 days by a 72-year-old male as a treatment for his mixed dyslipidaemia. At that point, the patient presented with asthenia, nausea, painless icterus, acholic stools and hyperchromic urine with biochemical analyses showing a dramatic increase in bilirubin (total bilirubin 22 mg/dL; direct bilirubin 21 mg/dL) and alkaline phosphatase (up to 4-fold over the normal level) with less marked increases in transaminases. Liver histology showed a pattern of cholestasis with evident signs of cholangiolitis and damage of the interlobular bile ducts. Serum transaminase and bilirubin levels returned to normal within 5 months after atorvastatin withdrawal while alkaline phosphatase normalized after only 8 months. Scores on both the Maria and Victorino clinical scale for the diagnosis of drug-induced hepatitis and the Naranjo Adverse Drug Reaction Probability Scale indicated that atorvastatin was the probable cause of prolonged cholestasis in this patient. This is a rare case of cholestasis probably caused by atorvastatin and unusually characterized by bile duct damage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20155993     DOI: 10.2165/11531660-000000000-00000

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  25 in total

1.  Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves.

Authors:  J Jiménez-Alonso; J M Osorio; F Gutiérrez-Cabello; A López de la Osa; L León; J D Mediavilla García
Journal:  Arch Intern Med       Date:  1999 Aug 9-23

2.  Comparison of the frequency of adverse events in patients treated with atorvastatin or simvastatin.

Authors:  Heather M Abourjaily; Alawi A Alsheikh-Ali; Richard H Karas
Journal:  Am J Cardiol       Date:  2003-04-15       Impact factor: 2.778

3.  Acute cholestatic hepatitis after reinitiating treatment with atorvastatin.

Authors:  Ezequiel Ridruejo; Oscar G Mandó
Journal:  J Hepatol       Date:  2002-07       Impact factor: 25.083

Review 4.  Atorvastatin associated liver disease.

Authors:  A T Clarke; P R Mills
Journal:  Dig Liver Dis       Date:  2006-06-13       Impact factor: 4.088

5.  Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia.

Authors:  C S Recto; S Acosta; A Dobs
Journal:  Clin Cardiol       Date:  2000-09       Impact factor: 2.882

6.  An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor.

Authors:  D M Black; R G Bakker-Arkema; J W Nawrocki
Journal:  Arch Intern Med       Date:  1998-03-23

7.  Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients.

Authors:  Connie B Newman; Gary Palmer; Halit Silbershatz; Michael Szarek
Journal:  Am J Cardiol       Date:  2003-09-15       Impact factor: 2.778

Review 8.  Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.

Authors:  H S Yee; N T Fong
Journal:  Ann Pharmacother       Date:  1998-10       Impact factor: 3.154

Review 9.  Statins and elevated liver tests: what's the fuss?

Authors:  Edward Onusko
Journal:  J Fam Pract       Date:  2008-07       Impact factor: 0.493

10.  Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury.

Authors:  Ayako Suzuki; Nancy Yuen; John Walsh; Julie Papay; Christine M Hunt; Anna Mae Diehl
Journal:  Clin Gastroenterol Hepatol       Date:  2009-04-09       Impact factor: 11.382

View more
  5 in total

1.  Effects of statins on cholestasis: good, bad or indifferent?

Authors:  Rahul Kuver
Journal:  J Gastroenterol Hepatol       Date:  2011-10       Impact factor: 4.029

Review 2.  Statin-induced Liver Injury Patterns: A Clinical Review.

Authors:  Leon D Averbukh; Alla Turshudzhyan; David C Wu; George Y Wu
Journal:  J Clin Transl Hepatol       Date:  2022-01-10

3.  miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity.

Authors:  Ryan M Allen; Tyler J Marquart; Carolyn J Albert; Frederick J Suchy; David Q-H Wang; Meenakshisundaram Ananthanarayanan; David A Ford; Angel Baldán
Journal:  EMBO Mol Med       Date:  2012-07-05       Impact factor: 12.137

4.  Virtual pathway explorer (viPEr) and pathway enrichment analysis tool (PEANuT): creating and analyzing focus networks to identify cross-talk between molecules and pathways.

Authors:  Marius Garmhausen; Falko Hofmann; Viktor Senderov; Maria Thomas; Benjamin A Kandel; Bianca Hermine Habermann
Journal:  BMC Genomics       Date:  2015-10-14       Impact factor: 3.969

5.  Atorvastatin alters the expression of genes related to bile acid metabolism and circadian clock in livers of mice.

Authors:  Wen-Kai Li; Huan Li; Yuan-Fu Lu; Ying-Ying Li; Zidong Donna Fu; Jie Liu
Journal:  PeerJ       Date:  2017-05-18       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.